ReviewEuropean urology2009
Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
Review in European urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 7 syntheses or guidelines pooled it, 450 citations in OpenAlex.
- Association between preoperative serum testosterone levels and the risk of postoperative erectile function after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.World journal of urology · 2025Pooled it
- Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.Nature communications · 2025Pooled it
- The role of endogenous testosterone in relationship with low- and intermediate-risk prostate cancer: a systematic review.Asian journal of andrology · 2024Pooled it
- An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate.Frontiers in endocrinology · 2024Pooled it
- The effect of different administrations of testosterone therapy on adverse prostate events: A Bayesian network meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Pooled it
- The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2014Pooled it
- A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.World journal of urology · 2020Trial
- Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.The Journal of clinical endocrinology and metabolism · 2016Trial
- Exercise improves the effects of testosterone replacement therapy and the durability of response after cessation of treatment: a pilot randomized controlled trial.Asian journal of andrologyTrial
- Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study).Asian journal of andrologyTrial
- Update on testosterone deficiency and therapeutic options for testosterone replacement therapy.Nature reviews. Urology · 2026Review
- Testosterone Therapy After TRAVERSE: Rethinking Cardiovascular and Prostate Cancer Safety.Balkan medical journal · 2026Article
- Cardiovascular Disease and Androgens: Clinical Trends, Potential Mechanisms, and Considerations for Engineering Solutions.Cardiovascular engineering and technology · 2026Review
- [Prevention instead of remediation-screening, lifestyle factors, and prostate care 2.0-transition of urology to healthcare coach : Holistic approach to prostate health].Urologie (Heidelberg, Germany) · 2026Review
- Is Male Hypogonadism a Risk Factor for Cancer Through Weakening of the Immune System?International journal of molecular sciences · 2026Review
- Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study.The Journal of urology · 2026Article
- The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review.Cureus · 2026Review
- Oncological Safety of Testosterone Replacement Therapy in Men With a History of Prostate Cancer: A Systematic Review.Cureus · 2026Review
- Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials.International journal of impotence research · 2026Review
121 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe traditional belief that prostate cancer (PCa) growth is dependent on serum testosterone (T) level has been challenged by recent negative studies in noncastrated men.
objectiveTo provide an improved framework for understanding the relationship of PCa to serum T level that is consistent with current evidence and is based on established biochemical principles of androgen action within the prostate. EVIDENCE ACQUISITION: A literature search was performed of publications dating from 1941 to 2008 that addressed experimental and clinical effects of androgens on prostate growth. Review of studies investigating the prostatic effects of manipulation of androgen concentrations in human and animal studies, and in PCa cell lines. EVIDENCE SYNTHESIS: Prostate growth is exquisitely sensitive to variations in androgen concentrations at very low concentrations, but becomes insensitive to changes in androgen concentrations at higher levels. This pattern is consistent with the observation that androgens exert their prostatic effects primarily via binding to the androgen receptor (AR), and that maximal androgen-AR binding is achieved at serum T concentrations well below the physiologic range. A Saturation Model is proposed that accounts for the seemingly contradictory results in human PCa studies. Changes in serum T concentrations below the point of maximal androgen-AR binding will elicit substantial changes in PCa growth, as seen with castration, or with T administration to previously castrated men. In contrast, once maximal androgen-AR binding is reached the presence of additional androgen produces little further effect.
conclusionsThe evidence clearly indicates that there is a limit to the ability of androgens to stimulate PCa growth. A Saturation Model based on androgen-AR binding provides a satisfactory conceptual framework to account for the dramatic effects seen with castration as well as the minor impact of T administration in noncastrated men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.